🔴 BioXcel Therapeutics is trading 10.39% down today after second-quarter results missed EPS and revenue estimates

BioXcel Therapeutics is trading 10.39% down at $0.80 after its August 17, 2026, second-quarter results missed expectations.

• EPS was -$0.490 versus -$0.423 estimated, while revenue was $182K versus $403.32K expected.
• Results highlighted financial pressure, including $13.8 million in cash and substantial ongoing losses.
• The decline follows a 25.21% drop on August 17; broader markets are also weaker, but the earnings disappointment is the clearest catalyst.